Engineered Antibodies as Cancer Radiotheranostics

Area of Science:

• Oncology
• Radiochemistry
• Immunology

Background:

• Radiotheranostics combines diagnostic imaging and radiotherapy for personalized medicine, particularly in cancer treatment.
• Radiolabeled antibodies are key tools in cancer theranostics due to their specificity for cancer antigens.
• Limitations of antibodies include large size, immune activity, and long half-lives, hindering tumor penetration and increasing radiation exposure.

Purpose of the Study:

• To provide an overview of antibody engineering for tumor radiotheranostics.
• To discuss methods for enhancing radioimmunoconjugates using antibody engineering.
• To explore radionuclide selection, conjugation techniques, and future directions in antibody radionuclide conjugate development.

Main Methods:

• Review of antibody engineering strategies for enhancing radioimmunoconjugates.
• Discussion of pharmacokinetic optimization, site-specific bioconjugation, Fc interaction modulation, and bispecific construct creation.
• Analysis of radionuclide choices and conjugation techniques for antibody radionuclide conjugates.

Main Results:

• Antibody engineering addresses limitations of native antibodies for radiopharmaceutical applications.
• Key engineering strategies include optimizing pharmacokinetics, enabling site-specific conjugation, modulating Fc interactions, and creating bispecific constructs.
• The review covers radionuclide selection and conjugation methods for improved antibody radionuclide conjugates.

Conclusions:

• Antibody engineering is crucial for overcoming challenges and advancing antibody-based radiotheranostics.
• Optimized antibody constructs offer improved tumor targeting, efficacy, and safety profiles.
• Further innovation in antibody radionuclide conjugates holds significant promise for personalized cancer therapy.